Interferon-beta 1B in the treatment of remittent-recurrent multiple sclerosis. The clinical experience of the Valencia group;Interferon-beta 1B en el tratamiento de la esclerosis multiple remitente-recurrente. Experiencia clinica del grupo de Valencia

Revista de Neurologia

Volumn 25, Issue 148, 1997, Pages 1876-1879

  Burguera, J A ^a   Casanova, B ^a,f   Cervello A ^b   Coret, F ^c   Del Olmo, A ^d   Palao, J ^c   Taberner, P ^d   Villarroya, T ^e  

^a Hospital Universitari La Fe

^b HÔPITAL DU BOCAGE   (France)

^c Hospital Clínic Universitari

^d Hospital Dr Peset Aleixandre

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Immunology; Interferon beta; Multiple sclerosis; Therapeutics; Valencia

Indexed keywords

INTERFERON BETA SERINE; METHYLPREDNISOLONE; STEROID; THYROXINE; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEMYELINATING DISEASE; DEPRESSION; HUMAN; HYPOTHYROIDISM; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; STEROID THERAPY; THYROIDITIS; TREATMENT OUTCOME; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HOSPITALIZATION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; SPAIN; THYROID GLAND;

ADJUVANTS, IMMUNOLOGIC; ADULT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION, SPONTANEOUS; SEVERITY OF ILLNESS INDEX; SPAIN; THYROID GLAND;

EID: 0031413877     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. The IFNB Multiple Sclerosis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
2. The IFNB Multiple Sclerosis Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
3. Informe del Subcomité de Normas de Calidad de la Academia Americana de Neurología. Recomendaciones prácticas para la selección de pacientes con esclerosis múltiple y su tratamiento con Betaferón. Neurology 1994; 44: 1537-40.
4. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis. Report of a consensus conference. Neurology 1996: 46: 12-8.
5. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
6. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
7. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS: Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
8. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, et al and the Optic Neuritis Study Group. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Eng J Med 1993; 329: 1764-9.